Detalhe da pesquisa
1.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259589
2.
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Haematologica
; 103(9): 1511-1517, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29880613
3.
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Clin Cancer Res
; 26(14): 3589-3596, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32198151
4.
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.
Blood Adv
; 3(10): 1568-1573, 2019 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31101647